AI Article Synopsis
- Streptococcus pneumoniae is a major cause of serious infections like pneumonia and meningitis, with high rates of mortality and morbidity worldwide, and it has around 98 different serotypes.
- Current vaccines, such as PCV-13 and PPV-23, face issues like serotype replacement and ineffective immune responses in certain populations, including children and the elderly.
- The use of protein/peptide-based vaccines, enhanced with nanoparticles as adjuvants, offers a promising solution by improving immunogenicity and efficiency for better protection against Streptococcus pneumoniae infections.
Article Abstract
Streptococcus pneumoniae having almost 98 serotypes and being common cause of acute otitis media, pneumonia, bacteremia, meningitis etc., which results in high mortality and morbidity globally. Although vaccines like PCV-13 and PPV-23 are available, some problems like serotype replacement and poor immunogenicity in children, old age and immunocompromised people has been observed. To overcome these drawbacks protein/peptide-based vaccine can be a good strategy as these provides wide serotype coverage. However, immunogenicity of protein subunit vaccines is lower, that issue can be solved by using adjuvants. Recently nanoparticles as an adjuvant for vaccine delivery being used, which has provided not only good immunogenicity but also improved delivery and efficiency of protein-based vaccines. In this review we have discussed the latest advancement of nanoparticles-based protein/peptide vaccine delivery for Streptococcus pneumoniae.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2023.11.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!